• Save
MD Paediatrics (Part 2) - Overview of Clinical Trials
Upcoming SlideShare
Loading in...5
×
 

MD Paediatrics (Part 2) - Overview of Clinical Trials

on

  • 412 views

Brief overview of Clinical Trials

Brief overview of Clinical Trials

Statistics

Views

Total Views
412
Views on SlideShare
412
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Whether the drug reaches the cancerHow the drug behaves in the bodyHow cancer cells in the body respond to the drug
  • The safe dose rangeWhat the side effects areHow the body copes with the drugIf the treatment shrinks the cancer

MD Paediatrics (Part 2) - Overview of Clinical Trials MD Paediatrics (Part 2) - Overview of Clinical Trials Presentation Transcript

  • Clinical Trials Overview
  • Introduction • Sets of tests in medical research and drug development that generate safety and efficacy data for health intervention • i.e : information about adverse drug reactions and adverse effects of other treatments. e.g.: drugs, diagnostics, devices, therapy protocols
  • Classification – Intervention • Observational • Interventional
  • Classification - Purpose • Prevention trials – medicines, vitamins, vaccines, minerals, or lifestyle changes • Screening trials – best way to detect certain diseases or health conditions • Diagnostic trials – Find better tests or procedures for diagnosing • Treatment trials – experimental treatments, new combinations of drugs, new approaches to surgery or radiation therapy • Quality of life trials/supportive care trials • Compassionate use trials / expanded access trials – partially tested, unapproved therapeutics to a small number of patients who have no other realistic options • (U.S. N.I.H. classification)
  • Phases – Drug development T0 T1
  • Pre-Clinical • Nonhuman – Lab – Animal (Rats , Primates , etc) • Efficacy • Toxicity • Pharmacokinetics
  • Phases… • Phase 0: Pharmacodynamics and Pharmacokinetics • Phase 1: Screening for safety • Phase 2: efficacy of the drug, usually against a placebo • Phase 3: Final confirmation of safety and efficacy • Phase 4: Post Market Surveillance • Phase 5: Translational Research (Meta Analysis)
  • Phase 0 • First in Human Studies (FIH) /Proof of concept studies (POC) • Healthy subjects (10-15) • Single sub therapeutic dose (human microdosing studies) • Preliminary Pharmacodynamics & Phamacokinetics • Usually skipped (asses with Phase 01)
  • Phase 1 • Volunteers(Healthy and Unhealthy) (20-80) • 1st stage of testing human subjects – Safety (Pharmacovigillance ) – Tolerance – Pharmacodynamics and Pharmacokinetics • Safe dosage • Half life • Types – Single ascending dose studies – Multiple ascending dose studies – Food effect assements • Therapeutic misconception
  • Phase 2 • Phase 2A (IIA) – Assess dosing requirements • Phase 2B (IIB) – Study efficacy • Study Design – Case Series ,RCT • 100 -300 subjects
  • Phase 3 • Compare new treatments with the best currently available treatment – Confirms its effectiveness – Monitor side effects • Randomized controlled multicenter trials • Drug licensing studies (Pre-marketing Phase) • Large study groups (300- 3000 subjects)
  • Phase 4 • Postmerketing Surveillance • Safety Surveillance • Rare or long-term adverse effects over a much larger patient population • Harmful effects discovered by Phase IV trials may result in a drug being no longer sold, or restricted to certain uses – Eg: Roficoxib
  • Phase 5 • Comparative effectiveness research and community-based research
  • THANK YOU